Genomics Personalized Health Market

Genomics Personalized Health Market (Technology: NGS Platform, RT-PCR, Microarray, Genetic Analyzer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

Genomics Personalized Health Market Outlook 2034

  • The global industry was valued at US$ 9.1 Bn in 2023
  • It is estimated to advance at a CAGR of 12.2% from 2024 to 2034 and reach US$ 33.0 Bn by the end of 2034

Analyst Viewpoint

Rise in demand for early diagnosis is driving the genomics personalized health market size. Personalized genomics is essential for early screening, diagnosis, and individualized treatment as 80% of rare diseases have genetic origins.

Increase in investment in R&D activities is also boosting the genomics personalized health market trajectory. Vendors in the market are investing in human genetics, functional genomics, and Artificial Intelligence/Machine Learning (AI/ML) to expand their product portfolio.

Encouragement and emphasis on R&D are likely to offer lucrative genomics personalized health market opportunities to vendors. To improve R&D, manufacturers are decreasing trial sizes and increasing the speed to market.

Market Introduction

Genomic personalized health is a novel approach to healthcare that involves modifying a patient's medical treatment based on genetic information. It is an advanced system developed with a deeper understanding of the human genome.

Genomic personalized health can help identify a variety of complex conditions and help develop more specialized therapies and treatments based on genetic profiling. It can also eliminate certain traditional drugs that might not work or have side effects in a particular patient group.

Genomic personalized health plays a major role in personalized medicine. An individual's genetic profile can be used to decide prevention, diagnosis, and treatment. It can be employed to decide the appropriate drug or therapy at the right dose or schedule.

Attribute Detail
Drivers
  • Rise in Demand for Early Diagnosis
  • Increase in Investment in R&D Activities

Rise in Demand for Early Diagnosis Fueling Genomics Personalized Health Market Value

Globally, there is an increasing focus on early disease diagnosis and preventative healthcare. The detection of genetic risk factors and predispositions to diseases, such as cancer, cardiovascular diseases, and neurological disorders, is made possible by genomic testing.

Early diagnosis and best-practice treatment planning are made possible by personal genomics and disease risk assessment. Knowing one's genetic risks through personalized genomics enables people to take preventive action through lifestyle modifications and routine screenings. Hence, increase in demand for early diagnosis is propelling the genomics personalized health market development.

Genetic testing can predict a person's likelihood of developing diseases like colorectal or breast cancer. To reduce the risk of disease, high-risk persons can reduce their exposure to harmful substances, adopt more appropriate lifestyle choices, and use preventive medication.

Increase in Investment in R&D Activities Driving Market Progress

To enhance therapeutic applications, substantial funding is being directed to genomic research from the public and private sectors. R&D is particularly strong in fields such as population genomics, pharmacogenomics, precision oncology, and genetic disease diagnostics.

Genomic medicine is being advanced by large-scale sequencing projects such as the Asia 100K and the U.K.'s 100K Genomes Project. To jointly create genetic tests and solutions, biopharma businesses, technology companies, and diagnostic labs are increasingly forming alliances. These activities are augmenting the genomics personalized health market revenue.

To boost R&D, various pharmaceutical companies are contributing to genomic data-sharing programs. In December 2021, Seven Bridges Genomics, a bioinformatics ecosystem provider, announced the formation of a new subsidiary, the Unified Patient Network (UPN), to facilitate clinical research and collaboration between participating health systems and biopharma companies with a focus on advancing precision medicine and improving patient care.

Regional Outlook

Attribute Detail
Leading Region North America

According to the latest genomics personalized healthcare market analysis, North America held largest share in 2023. Increase in healthcare expenditure and rise in awareness of and demand for personalized medicine are propelling the market dynamics of the region.

Advancements in genomics technologies, presence of large pharmaceutical companies and research organizations, and rise in prevalence of chronic diseases are also fueling the genomics personalized health market share in North America.

Since personalized medicine is currently preferred for treating various types of illnesses, medication discovery and research on specific illnesses are interrelated. Various companies are developing customized diagnosis products.

In January 2021, Illumina, Inc. created the TruSight Oncology 500 (TSO 500) assay, which can effectively identify up to 523 cancer biomarkers using nucleic acids from the tumor.

Analysis of Key Players

Key players operating in the genomics personalized health market landscape are offering robust precision medicine genomics services and programs that leverage predictive analytics to provide targeted treatment regimens. These services help prevent and treat diseases at their earliest stages when they are most treatable.

In April 2021, NorthShore University HealthSystem (NorthShore) and health intelligence company Sema4 announced the rollout of a system-wide data-driven genomics initiative aimed at providing patients and their care team with early detection of disease onset.

QIAGEN, Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Hoffmann-La Roche AG, Lonza Group, Invitae Corp, Genetic Technologies Limited, Interleukin Genetics Inc., Eastern Biotech and Life Sciences, DNA Genotek Inc., uBiome, Inc., and XCode Life Sciences Private Limited are some of the key players operating in genomics personalized health industry.

These companies have been profiled in the genomics personalized health market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.

Key Developments in Genomics Personalized Health Market

  • In March 2023, Illumina Inc. announced the release of Connected Insights, a new cloud-based software enabling tertiary analysis for clinical next-generation sequencing (NGS) data, thereby assisting in deeper, and more comprehensive genomic studies
  • In September 2021, Invitae Corp., a medical genetics company, announced the acquisition of Ciitizen, a consumer health technology company. This acquisition will expand the consumer genomics product portfolio of Invitae Corp.

Genomics Personalized Health Market Snapshot

Attribute Detail
Market Size in 2023 US$ 9.1 Bn
Market Forecast (Value) in 2034 US$ 33.0 Bn
Growth Rate (CAGR) 12.2%
Forecast Period 2024-2034
Historical Data Available for 2020-2022
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2023)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • By Technology
    • NGS Platform
    • RT-PCR
    • Microarray
    • Genetic Analyzer
    • Others
  • By Test Type
    • Oncology Testing
    • Infectious Disease Testing
    • Orphan Disease Testing
    • Autoimmune Disease Testing
    • Obstetrics Testing
    • Others
  • By End-user
    • Academics & Research Institutes
    • Diagnostic Centers
    • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • QIAGEN
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Hoffmann-La Roche AG
  • Lonza Group
  • Invitae Corp
  • Genetic Technologies Limited
  • Interleukin Genetics Inc.
  • Eastern Biotech and Life Sciences
  • DNA Genotek Inc.
  • uBiome, Inc.
  • XCode Life Sciences Private Limited
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global genomics personalized health market in 2023?

It was valued at US$ 9.1 Bn in 2023

How is the genomics personalized health business expected to grow by 2034?

It is projected to advance at a CAGR of 12.2% from 2024 to 2034

What are the key factors driving the demand for genomics personalized health?

Rise in demand for early diagnosis and increase in investment in R&D activities

Which was the major region in the genomics personalized health landscape in 2023?

North America was the leading region in 2023

Who are the key genomics personalized health vendors?

QIAGEN, Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Hoffmann-La Roche AG, Lonza Group, Invitae Corp, Genetic Technologies Limited, Interleukin Genetics Inc., Eastern Biotech and Life Sciences, DNA Genotek Inc., uBiome, Inc., and XCode Life Sciences Private Limited

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Genomics Personalized Health Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Genomics Personalized Health Market Analysis and Forecast, 2020-2034

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Product /Brand Analysis

    5.3. Key Mergers & Acquisitions

    5.4. COVID-19 Pandemic Impact on Industry

6. Global Genomics Personalized Health Market Analysis and Forecast, By Technology

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, By Technology, 2020-2034

        6.3.1. NGS Platform

        6.3.2. RT-PCR

        6.3.3. Microarray

        6.3.4. Genetic Analyzer

        6.3.5. Others

    6.4. Market Attractiveness Analysis, By Technology

7. Global Genomics Personalized Health Market Analysis and Forecast, by Test Type

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Test Type, 2020-2034

        7.3.1. Oncology Testing

        7.3.2. Infectious Disease Testing

        7.3.3. Orphan Disease Testing

        7.3.4. Autoimmune Disease Testing

        7.3.5. Obstetrics Testing

        7.3.6. Others

    7.4. Market Attractiveness Analysis, by Test Type

8. Global Genomics Personalized Health Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by End-user, 2020-2034

        8.3.1. Academics & Research Institutes

        8.3.2. Diagnostic Centers

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by End-user

9. Global Genomics Personalized Health Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region, 2020-2034

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Genomics Personalized Health Market Analysis and Forecast

    10.1. Introduction

    10.2. Key Findings

    10.3. Market Value Forecast, By Technology, 2020-2034

        10.3.1. NGS Platform

        10.3.2. RT-PCR

        10.3.3. Microarray

        10.3.4. Genetic Analyzer

        10.3.5. Others

    10.4. Market Value Forecast, by Test Type, 2020-2034

        10.4.1. Oncology Testing

        10.4.2. Infectious Disease Testing

        10.4.3. Orphan Disease Testing

        10.4.4. Autoimmune Disease Testing

        10.4.5. Obstetrics Testing

        10.4.6. Others

    10.5. Market Value Forecast, by End-user, 2020-2034

        10.5.1. Academics & Research Institutes

        10.5.2. Diagnostic Centers

        10.5.3. Others

    10.6. Market Value Forecast, by Country, 2020-2034

        10.6.1. U.S.

        10.6.2. Canada

    10.7. Market Attractiveness Analysis

        10.7.1. By Technology

        10.7.2. By Test Type

        10.7.3. By End-user

        10.7.4. By Country

11. Europe Genomics Personalized Health Market Analysis and Forecast

    11.1. Introduction

    11.2. Key Findings

    11.3. Market Value Forecast, By Technology, 2020-2034

        11.3.1. NGS Platform

        11.3.2. RT-PCR

        11.3.3. Microarray

        11.3.4. Genetic Analyzer

        11.3.5. Others

    11.4. Market Value Forecast, by Test Type, 2020-2034

        11.4.1. Oncology Testing

        11.4.2. Infectious Disease Testing

        11.4.3. Orphan Disease Testing

        11.4.4. Autoimmune Disease Testing

        11.4.5. Obstetrics Testing

        11.4.6. Others

    11.5. Market Value Forecast, by End-user, 2020-2034

        11.5.1. Academics & Research Institutes

        11.5.2. Diagnostic Centers

        11.5.3. Others

    11.6. Market Value Forecast, by Country/Sub-region, 2020-2034

        11.6.1. Germany

        11.6.2. U.K.

        11.6.3. France

        11.6.4. Italy

        11.6.5. Spain

        11.6.6. Rest of Europe

    11.7. Market Attractiveness Analysis

        11.7.1. By Technology

        11.7.2. By Test Type

        11.7.3. By End-user

        11.7.4. By Country/Sub-region

12. Asia Pacific Genomics Personalized Health Market Analysis and Forecast

    12.1. Introduction

    12.2. Key Findings

    12.3. Market Value Forecast, By Technology, 2020-2034

        12.3.1. NGS Platform

        12.3.2. RT-PCR

        12.3.3. Microarray

        12.3.4. Genetic Analyzer

        12.3.5. Others

    12.4. Market Value Forecast, by Test Type, 2020-2034

        12.4.1. Oncology Testing

        12.4.2. Infectious Disease Testing

        12.4.3. Orphan Disease Testing

        12.4.4. Autoimmune Disease Testing

        12.4.5. Obstetrics Testing

        12.4.6. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2020-2034

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Technology

        12.6.2. By Test Type

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Genomics Personalized Health Market Analysis and Forecast

    13.1. Introduction

    13.2. Key Findings

    13.3. Market Value Forecast, By Technology, 2020-2034

        13.3.1. NGS Platform

        13.3.2. RT-PCR

        13.3.3. Microarray

        13.3.4. Genetic Analyzer

        13.3.5. Others

    13.4. Market Value Forecast, by Test Type, 2020-2034

        13.4.1. Oncology Testing

        13.4.2. Infectious Disease Testing

        13.4.3. Orphan Disease Testing

        13.4.4. Autoimmune Disease Testing

        13.4.5. Obstetrics Testing

        13.4.6. Others

    13.5. Market Value Forecast, by End-user, 2020-2034

        13.5.1. Academics & Research Institutes

        13.5.2. Diagnostic Centers

        13.5.3. Others

    13.6. Market Value Forecast, by Country/Sub-region, 2020-2034

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7. Market Attractiveness Analysis

        13.7.1. By Technology

        13.7.2. By Test Type

        13.7.3. By End-user

        13.7.4. By Country/Sub-region

14. Middle East & Africa Genomics Personalized Health Market Analysis and Forecast

    14.1. Introduction

    14.2. Key Findings

    14.3. Market Value Forecast, By Technology, 2020-2034

        14.3.1. NGS Platform

        14.3.2. RT-PCR

        14.3.3. Microarray

        14.3.4. Genetic Analyzer

        14.3.5. Others

    14.4. Market Value Forecast, by Test Type, 2020-2034

        14.4.1. Oncology Testing

        14.4.2. Infectious Disease Testing

        14.4.3. Orphan Disease Testing

        14.4.4. Autoimmune Disease Testing

        14.4.5. Obstetrics Testing

        14.4.6. Others

    14.5. Market Value Forecast, by End-user, 2020-2034

        14.5.1. Academics & Research Institutes

        14.5.2. Diagnostic Centers

        14.5.3. Others

    14.6. Market Value Forecast, by Country/Sub-region, 2020-2034

        14.6.1. GCC Countries

        14.6.2. South Africa

        14.6.3. Rest of Middle East & Africa

    14.7. Market Attractiveness Analysis

        14.7.1. By Technology

        14.7.2. By Test Type

        14.7.3. By End-user

        14.7.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

    15.2. Market Share Analysis, by Company (2023)

    15.3. Company Profiles

        15.3.1. QIAGEN

            15.3.1.1. Company Overview

            15.3.1.2. Product Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. Illumina, Inc.

            15.3.2.1. Company Overview

            15.3.2.2. Product Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. Thermo Fisher Scientific, Inc.

            15.3.3.1. Company Overview

            15.3.3.2. Product Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

            15.3.3.5. Strategic Overview

        15.3.4. Bio-Rad Laboratories, Inc.

            15.3.4.1. Company Overview

            15.3.4.2. Product Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. Hoffmann-La Roche AG

            15.3.5.1. Company Overview

            15.3.5.2. Product Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. Lonza Group

            15.3.6.1. Company Overview

            15.3.6.2. Product Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Financial Overview

            15.3.6.5. Strategic Overview

        15.3.7. Invitae Corp

            15.3.7.1. Company Overview

            15.3.7.2. Product Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Financial Overview

            15.3.7.5. Strategic Overview

        15.3.8. Genetic Technologies Limited

            15.3.8.1. Company Overview

            15.3.8.2. Product Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Financial Overview

            15.3.8.5. Strategic Overview

        15.3.9. Interleukin Genetics Inc.

            15.3.9.1. Company Overview

            15.3.9.2. Product Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Financial Overview

            15.3.9.5. Strategic Overview

        15.3.10. Eastern Biotech and Life Sciences

            15.3.10.1. Company Overview

            15.3.10.2. Product Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Financial Overview

            15.3.10.5. Strategic Overview

        15.3.11. DNA Genotek Inc.

            15.3.11.1. Company Overview

            15.3.11.2. Product Portfolio

            15.3.11.3. SWOT Analysis

            15.3.11.4. Financial Overview

            15.3.11.5. Strategic Overview

        15.3.12. uBiome, Inc.

            15.3.12.1. Company Overview

            15.3.12.2. Product Portfolio

            15.3.12.3. SWOT Analysis

            15.3.12.4. Financial Overview

            15.3.12.5. Strategic Overview

        15.3.13. XCode Life Sciences Private Limited

            15.3.13.1. Company Overview

            15.3.13.2. Product Portfolio

            15.3.13.3. SWOT Analysis

            15.3.13.4. Financial Overview

            15.3.13.5. Strategic Overview

List of Tables

Table 01: Global Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034

Table 02: Global Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034

Table 03: Global Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 04: Global Genomics Personalized Health Market Size (US$ Mn) Forecast, by Region, 2020-2034

Table 05: North America Genomics Personalized Health Market Size (US$ Mn) Forecast, by Country, 2020-2034

Table 06: North America Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034

Table 07: North America Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034

Table 08: North America Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 09: Europe Genomics Personalized Health Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 10: Europe Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034

Table 11: Europe Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034

Table 12: Europe Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 13: Asia Pacific Genomics Personalized Health Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 14: Asia Pacific Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034

Table 15: Asia Pacific Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034

Table 16: Asia Pacific Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 17: Latin America Genomics Personalized Health Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 18: Latin America Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034

Table 19: Latin America Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034

Table 20: Latin America Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 21: Middle East & Africa Genomics Personalized Health Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 22: Middle East & Africa Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034

Table 23: Middle East & Africa Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034

Table 24: Middle East & Africa Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

Figure 01: Global Genomics Personalized Health Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034

Figure 02: Global Genomics Personalized Health Market Revenue (US$ Mn), By Technology, 2023

Figure 03: Global Genomics Personalized Health Market Value Share, By Technology, 2023

Figure 04: Global Genomics Personalized Health Market Revenue (US$ Mn), by Test Type, 2023

Figure 05: Global Genomics Personalized Health Market Value Share, by Test Type, 2023

Figure 06: Global Genomics Personalized Health Market Revenue (US$ Mn), by End-user, 2023

Figure 07: Global Genomics Personalized Health Market Value Share, by End-user, 2023

Figure 08: Global Genomics Personalized Health Market Value Share, by Region, 2023

Figure 09: Global Genomics Personalized Health Market Value (US$ Mn) Forecast, 2020-2034

Figure 10: Global Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034

Figure 11: Global Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034

Figure 12: Global Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034

Figure 13: Global Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034

Figure 14: Global Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034

Figure 15: Global Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034

Figure 16: Global Genomics Personalized Health Market Value Share Analysis, by Region, 2023 and 2034

Figure 17: Global Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034

Figure 18: North America Genomics Personalized Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 19: North America Genomics Personalized Health Market Attractiveness Analysis, by Country, 2024-2034

Figure 20: North America Genomics Personalized Health Market Value Share Analysis, by Country, 2023 and 2034

Figure 21: North America Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034

Figure 22: North America Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034

Figure 23: North America Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034

Figure 24: North America Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034

Figure 25: North America Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034

Figure 26: North America Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034

Figure 27: Europe Genomics Personalized Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 28: Europe Genomics Personalized Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 29: Europe Genomics Personalized Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 30: Europe Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034

Figure 31: Europe Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034

Figure 32: Europe Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034

Figure 33: Europe Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034

Figure 34: Europe Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034

Figure 35: Europe Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034

Figure 36: Asia Pacific Genomics Personalized Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 37: Asia Pacific Genomics Personalized Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 38: Asia Pacific Genomics Personalized Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 39: Asia Pacific Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034

Figure 40: Asia Pacific Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034

Figure 41: Asia Pacific Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034

Figure 42: Asia Pacific Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034

Figure 43: Asia Pacific Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034

Figure 44: Asia Pacific Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034

Figure 45: Latin America Genomics Personalized Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 46: Latin America Genomics Personalized Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 47: Latin America Genomics Personalized Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 48: Latin America Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034

Figure 49: Latin America Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034

Figure 50: Latin America Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034

Figure 51: Latin America Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034

Figure 52: Latin America Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034

Figure 53: Latin America Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034

Figure 54: Middle East & Africa Genomics Personalized Health Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 55: Middle East & Africa Genomics Personalized Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 56: Middle East & Africa Genomics Personalized Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 57: Middle East & Africa Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034

Figure 58: Middle East & Africa Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034

Figure 59: Middle East & Africa Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034

Figure 60: Middle East & Africa Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034

Figure 61: Middle East & Africa Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034

Figure 62: Middle East & Africa Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034

Copyright © Transparency Market Research, Inc. All Rights reserved